The slow rate and late reporting of results is just giving time for assets like SurVaxM to gain more momentum. The multiple shots on goal strategy requires a cash runway to see the data. A more typical strategy is to to focus in PII on one pathway to NDA then branch out. Derisking one path to market affords an inflection point and then cash to pursue more shots. Opening endless trials, even those 'run by others' burns through our dwindling cash reserves. Supporting trials with drug and even a fraction of managements salaries costs us each time we open a trial. Positive dipg or interim brain mets data in the next month will inject life back, just don't suck it back out with ATM's! They don't get this data out, as they have promised, then we will rapidly head back under 10c and yet another reverse split in the USA. Dr. Friend needs to report before June 30th.
KZA Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
